Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 71-75

  Peet, M ^a   Laugharne, J D E ^a   Mellor, J ^a   Ramchand, C N ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; MEMBRANE PHOSPHOLIPID;

CONFERENCE PAPER; DIET; DIET SUPPLEMENTATION; ERYTHROCYTE MEMBRANE; ESSENTIAL FATTY ACID DEFICIENCY; HUMAN; INHERITANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0029742376     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90148-9     Document Type: Conference Paper

References (33)

1. Torrey E. F. Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull 1992; 18: 159-170.
2. McGuffin P., Asherton P., Owen M., Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatr 1995; 164: 593-599.
3. Obi F. O., Nwanze E. A. C. Fatty acid profiles in mental disease. I Linoleate variations in schizophrenia. J Neurol Sci 1979; 43: 447-454.
4. Horrobin D. F., Manku M. S., Morse-Fisher N. et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatr 1989; 25: 562-568.
5. Kaiya H., Horrobin D. F., Manku M. S., Fischer N. M. Essential and other fatty acids in plasma from schizophrenics and normal individuals from Japan. Biol Psychiatr 1991; 30: 357-362.
6. Bates C., Horrobin D. F., Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identifical twins concordant and discordant for schizophrenia. Schizophr Res 1992; 6: 1-7.
7. Vaddadi K. S., Courtney P., Gilleard C. J., Manku M. S., Horrobin D. F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia, Psychiatr Res 1989; 27: 313-323.
8. Peet M., Laugharne J., Rangarajan N., Horrobin D., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995; 29: 227-232.
9. Glen A. I. M., Glen E. M. T., Horrobin D. et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr Res 1994; 12: 53-61.
10. Peet M., Laugharne J., Horrobin D., Reynolds G. Arachidonic acid: a common link in the biology of schizophrenia? Arch Gen Psychiatr 1994; 51: 665-666.
11. Mellor J. E., Laugharne J. D. E., Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacol, in press.
12. Mellor J. E., Laugharne J. D. E., Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res, in press.
13. Nocon H., Melzacka M. Effect of some cationic amphiphilic drugs on phospholipid methylation in the central nervous system of rats. J Pharm Pharmacol 1991; 43: 107-110.
14. Leli U. Modification of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. Biochem Pharmacol 1987; 36: 31-37.
15. Maziere C., Maziere J.-C., Mora L., Auclair M., Polonovski J. Tnfluoperazine increases fatty acid turnover in phospholipids in cultured human fibroblasts. Lipids 1988; 23: 419-423.
16. Fischer S., Kissling W., Kuss H.-J. Schizophrenic patients treated with high dose phenothiazine or thioxanthine become deficient in polyunsaturated fatty acids in their thrombocytes. Biochem Pharmacol 1992; 44: 317-323.
17. Yao J. K., Van Kammen D. P., Welker J. A. Red cell membrane dynamics in schizophrenia II: Fatty acid composition. Schizophr Res 1994; 13: 217-226.
18. Morrow J. D., Frei B., Longmire A. W. et al. Increase in circulating products of lipid peroxidation (F2- isoprostanes) in smokers. N Engl J Med 1995; 332: 1198-1203.
19. Pettegrew J. W., Kesharan M. S., Panchalingoim K., Strychor S., Kaplan D. B., Tretta M. G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in drug-naive, first episode schizophrenics. Arch Gen Psychiatr 1991; 48: 563-568.
20. Stanley J. A., Williamson P. C., Drost D. J., Carr T. J., Rylett J., Malla A., Thompson T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorous magnetic resonance spectroscopy. Arch Gen Psychiatr 1995; 52: 399-406.
21. Deicken R. F., Calabrese G., Merrin E. L., Meyerhoff D. J., Dillon W. P., Weiner M. W., Fein G. 13-Phosphorous magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatr 1994; 36: 503-510.
22. Demisch L., Gerbaldo H., Gebhart P., Georgi K., Bochnik H. J. Incorporation of 14C arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disorders. Psychiatr Res 1987; 22: 275-282.
23. Van Gossum A., Decuyper J. Breath alkanes as an index of lipid peroxidation. Eur Respir J 1989; 2: 787-791.
24. Kovaleva E. S., Orlov O. N., Tsutsulkovskaia M. I. A., Vladimorova T. V., Beliaev B. S. Lipid peroxidation processes in patients with schizophrenia. Zh Neuropatol Psikiatr 1989; 89: 108-110.
25. Phillips M., Sabas M., Greenberg J. Increased pentane and carbon disulphide in the breath of patients with schizophrenia. J Clin Pathol 1993; 46: 861-864.
26. Mahadik S. P., Mukherjee S., Correnti E. E., Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr Res 1995; 15: 66.
27. Gattaz W. F., Schmitt A., Maras A. Increased platelet phospholipase A2 in schizophrenia. Schizophr Research 1995; 16: 1-6.
28. Abdalla D. S. P., Manteiro H. P., Olivera J. A. C., Bechara C. H. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 1986; 32: 805-807.
29. Reddy R., Sahebarao M. M., Mukherjee S., Murthy J. N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatr 1991; 30: 409-412.
30. Buckman T. D., Kling A. S., Eiduson S., Sutphin M. S., Steinberg A. Glutathione peroxidase and C T scan abnormalities in schizophrenia. Biol Psychiatr 1987; 22: 349-356.
31. Christensen O., Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78: 587-591.
32. Wolkin A., Jordan B., Peselow E., Rubinstein M., Retrosen J. Essential fatty acid supplementation in tardive dyskinesia. Arn J Psychiatr 1986; 143: 912-914.
33. Rudin D. O. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatr 1981; 16: 837-848.